## CRSP: CRISPR Therapeutics AG - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 3.9% below STRENGTH zone (4.0-10.0%); PEG unavailable fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($51.57)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 4
- **Sentiment:** Neutral (Bullish: 2, Bearish: 0)

**1. CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112â„¢) in Autoimmune Diseases and Hematologic Malignancies**
- Source: GlobeNewswire | 20251222T131013 | Bullish | Relevance: 100%
- CRISPR Therapeutics announced encouraging preliminary data for zugocaptagene geleucel (zugo-cel) in autoimmune diseases, showing deep B-cell depletion and significant clinical improvement, including remission in a SLE patient. The company also reported positive single-agent activity in relapsed or refractory large B-cell lymphoma, with a high overall response rate. Additionally, a new Phase 1 basket trial for zugo-cel has been initiated in ITP and wAIHA, and a collaboration with Lilly to evaluate zugo-cel with pirtobrutinib in aggressive B-cell lymphomas was established.

**2. How Investors May Respond To CRISPR Therapeutics (CRSP) Earnings Amid Slow Casgevy Uptake Concerns**
- Source: Simply Wall Street | 20251220T220859 | Somewhat-Bearish | Relevance: 100%
- CRISPR Therapeutics is facing investor scrutiny ahead of an earnings report expected to show a significant decline in earnings and revenue. Despite the market approval of its gene-editing therapy, Casgevy, its slow commercial uptake is raising concerns about the company's near-term business momentum. The article suggests that the current share pullback reflects sentiment on Casgevy's launch, highlighting the need for clearer uptake data and progress in other pipeline projects to address investor worries about cash burn.

**3. How Investors May Respond To CRISPR Therapeutics (CRSP) Earnings Amid Slow Casgevy Uptake Concerns**
- Source: Simply Wall Street | 20251220T100908 | Somewhat-Bearish | Relevance: 100%
- CRISPR Therapeutics is facing investor scrutiny ahead of an earnings report expected to show a significant decline in earnings and revenue. This comes despite the approval of its gene-editing therapy, Casgevy, whose slow initial uptake is contrasting with the company's strong balance sheet, raising questions about near-term momentum and long-term prospects in gene editing. The market is weighing Casgevy's commercial progress against ongoing losses, leading to diverse fair value estimates among analysts.

**4. CRISPR Therapeutics CRISPR Therapy Shows 90% Response Rate In Aggressive Blood Cancer**
- Source: Benzinga | 20251222T181013 | Bullish | Relevance: 100%
- CRISPR Therapeutics provided an update on zugocaptagene geleucel (zugo-cel), an investigational allogeneic CAR T therapy. The therapy showed a 90% overall response rate and 70% complete response rate in patients with relapsed/refractory large B-cell lymphoma (LBCL), with encouraging preliminary data also seen in autoimmune rheumatologic diseases. The company is collaborating with Eli Lilly and Co. to further develop zugo-cel in aggressive B-cell lymphomas.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-26 | Chardan Capital | $74 | $82 | -10% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-26 | Chardan Capital | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 5 ($0.00M) |
| Sells | 5 ($3.81M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 45.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- ARK Investment Manag: 10.3% (-3.9%)
- Blackrock Inc.: 7.4% (+16.2%)
- Capital Internationa: 5.9% (+1.0%)
- Orbis Allan Gray Ltd: 5.2% (+80.2%)
- State Street Corpora: 4.2% (+22.5%)

### Key Risks

1. Insider selling cluster: $3.8M in recent transactions.
2. High short interest (26.4%, 8.9 days to cover): squeeze risk or crowded bearish bet.
3. Market regime shift could impact high-beta names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

Balance sheet: strong liquidity (16.2x), low leverage (D/E 0.17). Revenue growth strong at 1916% YoY. Analyst sentiment negative (1 target cuts vs 0 raises). Insider selling cluster ($3.8M in 90 days), potential headwind. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $5.5B |
| Beta | 1.73 |
| 52W Range | $30.04 - $78.48 |
| Short Interest | 26.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | -0.21 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_20 improving modestly (+0.9% over 5 days). Below STRENGTH zone by 0.1pp (needs >4.0% for momentum thesis). MRS_5 at 2.3% confirms short-term momentum alignment. AM_20 at 4.5% shows strong absolute momentum above own 20MA. Outperforming sector by 4.0pp, stock-specific strength. RSI neutral at 55. OFD pattern: +SLN (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 3.87% (CS: 79) | Neutral |
| RSI_14 | 55.2 | Neutral |
| MACD Histogram | 0.34 | Bullish |
| vs SMA20 | 1.045x | Above |
| vs SMA50 | 0.987x | Below |
| vs SMA200 | 1.132x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $57.91
- **Stop Loss:** $51.57 (10.9% risk)
- **Target:** $64.25 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 189
- **Position Value:** $10,944.99
- **Portfolio %:** 10.94%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite. VIX decline to 52-week lows and moderate breadth recovery suggest calming conditions, though narrow participation indicates selectivity remains key. Positive earnings momentum and AI adoption themes provide fundamental support for quality growth names.*

### Earnings

**Next:** 2026-02-18 (Est: $-1.23)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-1.29 | $-1.17 | +9.2% |
| 2025Q2 | $-1.40 | $-1.29 | +7.8% |
| 2025Q1 | $-1.28 | $-1.58 | -23.8% |
| 2024Q4 | $-1.19 | $-0.44 | +62.9% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*